Simply Wall St.
Should FDA Accelerated Approval Pathway for ST-920 Gene Therapy Data Require Action From Sangamo Therapeutics (SGMO) Investors?
📊
AI Sentiment
Positive
7/10
Sangamo Therapeutics Inc. News
Latest updates and market news for SGMO
6 news
Feb 3 - Feb 9, 2026
Page 1
GlobeNewswire
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposiumâ„¢ 2026
📈
AI Sentiment
Highly Positive
9/10
MT Newswires
Sector Update: Health Care Stocks Softer Late Afternoon
📉
AI Sentiment
Negative
3/10
MT Newswires
Sangamo Shares Fall After Pricing $25 Million Public Offering
📉
AI Sentiment
Negative
2/10
GlobeNewswire
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
âž–
AI Sentiment
Neutral
4/10
Share this news page